Navigation Links
Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
Date:11/25/2008

RICHMOND, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 4:30 pm (ET) on Tuesday, December 2, 2008 at the Piper Jaffray 20th Annual Health Care Conference in New York. The company will also update the financial community on its latest developments in its therapeutic programs and discuss other business matters at its annual Investor and Analyst Briefing to be held from 4:30 to 6:30 pm ET, on Wednesday, December 3, 2008.

The presentations will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentations will be archived on the Sangamo website for two weeks after the events.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Other therapeutic development programs are focused on cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP TF technology platform, strategic partnerships with collaborators and clinical trials of ZFP Therapeutics. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, uncertainties relating to the initiation and completion of stages of ZFP Therapeutic clinical trials, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
2. Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
3. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
4. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
5. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
6. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
7. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
8. Sangamo BioSciences to Present at the Canaccord Adams Global Growth Conference
9. Sangamo BioSciences to Present at the BMO Capital Markets Focus on Healthcare Conference
10. Sangamo BioSciences Reports Second Quarter 2008 Financial Results
11. Sangamo BioSciences Announces Second Quarter Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... ... January 11, 2017 , ... Ovation Fertility™ Genetics now ... preimplantation genetic screening (PGS). , “Our genetics and IVF teams are recognized experts ... Scientific Director Amy Jones, M.S., ELD (ABB) , who has worked with ...
(Date:1/11/2017)... ... 11, 2017 , ... Photonics industry and STEM advocates associated ... the U.S. Congress and President Obama for their recognition of the importance of ... Innovation and Competitiveness Act (AICA). , The language of the act (S. 3084) ...
(Date:1/11/2017)... Ca (PRWEB) , ... January 11, 2017 , ... ... U.S. each year and costing healthcare systems more than $23.7 billion, healthcare ... controlling costs. , Among the most common sepsis-causing pathogens are bacteria and ...
(Date:1/11/2017)... ... 11, 2017 , ... Microbial genomics leader uBiome, is awarding ... recent microbiome impact grant award has been made to Dr. Eon Rios of ... of oral antibiotics, prescribed for skin conditions, on the gut microbiome. , ...
Breaking Biology Technology:
(Date:1/11/2017)...  Michael Johnson, co-founder of Visikol Inc. a company originally funded ... named to the elite "Forbes 30 Under 30" list in the ... in 20 fields nationwide to be recognized as a leader in ... selected. ... currently a PhD candidate at Rutgers University. ...
(Date:1/4/2017)... Jan. 4, 2017  CES 2017 – Valencell ... technology, today announced the launch of two new ... the highly-accurate biometric sensor modules that incorporate the ... experience and expertise. The two new designs include ... for hearables, and Benchmark BW2.0, a 2-LED version ...
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   ... data sensor technology, and STMicroelectronics (NYSE: ... spectrum of electronics applications, announced today the launch ... kit for biometric wearables that includes ST,s compact ... Valencell,s Benchmark™ biometric sensor system. Together, ...
Breaking Biology News(10 mins):